Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) have received an average recommendation of “Hold” from the nine research firms that are presently covering the firm. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $13.07.
A number of brokerages recently weighed in on MRTX. HC Wainwright set a $10.00 price objective on shares of Mirati Therapeutics and gave the company a “buy” rating in a report on Saturday, March 11th. Jefferies Group LLC reiterated a “hold” rating and issued a $5.50 price target (up previously from $5.00) on shares of Mirati Therapeutics in a research note on Saturday, March 11th. Finally, Zacks Investment Research upgraded shares of Mirati Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, May 3rd.
A number of hedge funds have recently added to or reduced their stakes in MRTX. KCG Holdings Inc. acquired a new stake in Mirati Therapeutics during the first quarter valued at approximately $106,000. Teachers Advisors LLC boosted its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Teachers Advisors LLC now owns 23,097 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 4,311 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Mirati Therapeutics by 21.1% in the fourth quarter. Trexquant Investment LP now owns 26,432 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 4,599 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Mirati Therapeutics by 189.8% in the third quarter. Tower Research Capital LLC TRC now owns 20,214 shares of the biotechnology company’s stock valued at $134,000 after buying an additional 13,240 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Mirati Therapeutics by 22.9% in the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock valued at $328,000 after buying an additional 11,753 shares in the last quarter. Hedge funds and other institutional investors own 50.41% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://sportsperspectives.com/2017/05/19/mirati-therapeutics-inc-mrtx-receives-average-rating-of-hold-from-analysts-updated-updated.html.
Shares of Mirati Therapeutics (NASDAQ:MRTX) traded up 1.39% during mid-day trading on Monday, reaching $3.65. 48,239 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $4.31 and a 200 day moving average price of $5.17. The firm’s market capitalization is $91.03 million. Mirati Therapeutics has a 12-month low of $3.10 and a 12-month high of $19.25.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Thursday, March 9th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.02. Analysts anticipate that Mirati Therapeutics will post ($3.31) EPS for the current fiscal year.
Mirati Therapeutics Company Profile
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.